Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. develops and commercializes nitric oxide-based medical device and biopharmaceutical programs. Its recurring news centers on LungFit PH, a tankless inhaled nitric oxide system that uses Plasma Pulse Technology to generate nitric oxide from room air, and on commercial access through hospital purchasing channels.
Company updates also cover nitric oxide programs for respiratory indications, including severe lung infections, and Beyond Cancer's ultra-high concentration nitric oxide, or UNO, platform for investigational solid-tumor immunotherapy. Additional recurring themes include clinical data presentations, scientific publications, intellectual property, leadership changes, investor conferences, and governance matters.
Beyond Air, a company specializing in medical devices and biopharmaceuticals, has appointed David Webster as Chief Commercial Officer, effective July 8, 2024. Webster brings over 20 years of executive experience in the life sciences industry, including roles at Body Vision Medical and NeuroLogica. His appointment comes as Beyond Air's product, LungFit PH, is set to lead the nitric oxide (NO) market, with promising customer feedback and market engagement. The company granted Webster an inducement stock option to purchase 125,000 shares, vesting over four years. Webster's expertise is expected to drive significant market share gains for LungFit PH.
Beyond Cancer has revealed promising Phase 1a clinical data for their ultra-high concentration nitric oxide (UNO) platform, showing early tumor responses and immune system activation in subjects with relapsed or refractory unresectable solid tumors.
Data presented at the 2024 American Society of Clinical Oncology Annual Meeting highlighted immune biomarker responses, including increases in dendritic cells, cytotoxic T-cells, and central memory T-cells, along with a decrease of 54% in Myeloid Derived Suppressor Cells (MDSCs) post-treatment.
The Phase 1b trial, combining UNO with anti-PD-1 therapy, has been filed for regulatory approval and aims to enroll up to 20 subjects. UNO was generally well-tolerated, with primarily Grade 1 toxicities and one Grade 3 adverse event noted.
Beyond Air (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company, will announce its fiscal year-end 2024 financial results on June 24, 2024. The company, specializing in nitric oxide therapies for respiratory illnesses, neurological disorders, and solid tumors, will host a conference call and webcast at 4:30 pm ET on the same day. The call can be accessed domestically at 1-877-407-0784 and internationally at 1-201-689-8560 using Conference ID: 13746892. A live and replay webcast will be available on the company's website.
Beyond Cancer, has been chosen to present on the clinical development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting. The company will host an event in Chicago featuring key opinion leaders to discuss the ongoing clinical development of UNO. Additionally, presentations at the ASCO Annual Meeting will showcase new data from the Phase 1 trial evaluating UNO101 in various malignancies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.